Lancet
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Randomised trial in 1,444 peopleInterventions
52 weeks, multicentre, registered NCT03882970
The paper
1st Medical Department and Karl Landsteiner Institute for Obesity and Metabolic Disorders; Lilly Spain
Lancet, 6 Aug 2021
